Latest News

IEC Webcasts Available

Webcasts of IEC symposia on "Management of AD Patients on Systemic Treatments during COVID-19" is now available on-demand.

More Details
 

NEA Presents Eczema Expo 2020

The National Eczema Association will be holding its Eczema Expo 2020 virtually this year.

For further details, see https://nationaleczema.org/eczema-expo/

 

Coronavirus SECURE-AD Registry

SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion – Atopic Dermatitis; www.covidderm.org) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in AD patients who have been Covid-19 infected or where such an infection has been strongly suspected. 

More Details
 

IEC Statement on COVID 19

IEC would like to provide guidance on the use of systemic treatments for atopic dermatitis (AD; commonly called eczema) in the context of the COVID-19 pandemic, based on currently available pandemic and pharmacologic information.

More Details
 

IEC Introduces New Educational Modules for Clinical Investigators

The International Eczema Council is providing two new educational modules for atopic dermatitis (AD) clinical investigators.

More Details
 

Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale Now Available

Eli Lilly and Company (Lilly) has worked with numerous atopic dermatitis experts, including International Eczema Council advisors and Industry experts, to develop the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) scale for use in clinical trials.

More Details